The Brigham and Women's Hospital, Inc.

University of Michigan

Cornell University

Ventana Medical Systems, Inc.

Dana-farber-cancer Institute Inc.

Mark A Rubin

Francesca Demichelis

Arul M Chinnaiyan

Scott Tomlins

Daniel Rhodes

Rohit Mehra

Sven Perner

Charles Lee

Xiao-Wei Sun

Arun Sreekumar

Michael Otter

Phillip C Miller

Gary A Pestano

Karl Eric Garsha

Ray B Nagle

David S Rickman

Dorothee Pflueger

Levi A Garraway

William R Sellers

Himisha Beltran

Francesca DeMichelis

Karl Garsha

Bharathi Laxman

Sunita Setlur

Kirsten Mertz

Ya-Lin Chiu

Kyung Park

Juan Miguel Mosquera

Dimple Chakravarty

Christopher Barbieri

Gary Anthony Pestano

In general, the presently disclosed technology relates to identification of cancer subtypes. More specifically, the technology relates to methods for determining molecular drivers of cancer and/or progression using a multivariate image data and statistical analysis of in-situ molecular markers and morphological characteristics in the same cells of a biological sample suspected of b cancer. This analysis takes place after a single acquisition that obtains the molecular and anatomic morphology data in parallel. The analysis compares specific morphological and molecular markers to known samples exhibiting particular genetic drivers of the cancer. This method provides statistical information that allows for an increased confidence in the identification of specific molecular drivers of the cancer.

Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology

The invention relates generally to new prostate cancer markers, and particularly to a class of cancer marked by the presence of missense mutations in SPOP, an E3 ubiquitin ligase component. The invention provides methods and materials for detecting and diagnosing prostate cancer by detecting these mutations and may be useful in predicting disease progression and response to therapy.

Recurrent SPOP mutations in prostate cancer

This invention relates to diagnosis and prognosis of prostate cancer, as well as therapeutic treatment of prostate cancer. More specifically, the invention provides diagnostic and prognostic methods based on detecting nuclear enriched abundant transcript 1 (NEAT1) levels in a sample. Further provided are methods for treating prostate cancer based on targeting NEAT1 via interfering RNA.

NEAT1 as a prognostic marker and therapeutic target for prostate cancer

Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.

Recurrent gene fusions in prostate cancer

Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis

This invention relates to a triple immunostaining assay (ERG/TFF3/HMWCK) for sensitive and specific detection of prostate cancer. Positive staining for at least one of ERG or TFF3 combined with negative staining of HMWCK in a sample such as prostate tissue sample is indicative of cancer.

ERG/TFF3/HMWCK triple immunostain for detection of prostate cancer

Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.

Molecular subtyping, prognosis and treatment of prostate cancer

RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.

Compositions and methods for diagnosing prostate cancer based on detection of SLC45A3-ELK4 fusion transcript

An in depth analysis of prostate cancer prostatectomy samples which over-express the ERG oncogene led to the discovery of a novel gene translocation in prostate cancer, between the NDRG1 gene (N-myc downstream regulated gene 1) on chromosome 8 and the ERG oncogene on chromosome 21, leading to the expression of a chimeric NDRG1-ERG protein. Methods and compositions useful for diagnosing and treating prostate cancer characterized by NDRG1-ERG fusion are described.

Methods of diagnosing and treating prostate cancer characterized by NDRG1-ERG fusion

The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor.

Identification and treatment of estrogen responsive prostate tumors

Growing community of inventors

New York, NY, United States of America

Mark A Rubin